Natera Inc (NTRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Natera Inc (NTRA) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($40.17 Million) by net assets ($1.77 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NTRA equity to assets ratio to measure how much of total assets are equity-financed.
Natera Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Natera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Natera Inc (NTRA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Natera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Natera Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ameriprise Financial Inc
NYSE:AMP
|
0.074x |
|
Interactive Brokers Group Inc
NASDAQ:IBKR
|
0.170x |
|
Erste Group Bank AG
VI:EBS
|
0.070x |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
-0.236x |
|
Haleon plc
NYSE:HLN
|
0.090x |
|
Banco Bradesco DRC
BA:BBD
|
0.005x |
|
Legrand SA
PA:LR
|
0.059x |
|
LEGRAND UNSP.ARD 1/5 EO 4
F:LRC0
|
0.033x |
Annual Cash Flow Conversion Efficiency for Natera Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Natera Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Natera Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.71 Billion | $215.30 Million | 0.126x | +10.79% |
| 2024-12-31 | $1.20 Billion | $135.66 Million | 0.113x | +135.17% |
| 2023-12-31 | $765.33 Million | $-246.96 Million | -0.323x | +47.22% |
| 2022-12-31 | $705.74 Million | $-431.50 Million | -0.611x | -19.15% |
| 2021-12-31 | $653.30 Million | $-335.24 Million | -0.513x | -36.71% |
| 2020-12-31 | $486.24 Million | $-182.51 Million | -0.375x | -64.90% |
| 2019-12-31 | $278.71 Million | $-63.44 Million | -0.228x | +89.63% |
| 2018-12-31 | $32.16 Million | $-70.58 Million | -2.195x | +42.98% |
| 2017-12-31 | $25.42 Million | $-97.83 Million | -3.849x | -453.40% |
| 2016-12-31 | $106.48 Million | $-74.05 Million | -0.695x | -239.66% |
| 2015-12-31 | $184.76 Million | $-37.83 Million | -0.205x | -234.43% |
| 2014-12-31 | $-171.34 Million | $10.49 Million | -0.061x | -143.51% |
| 2013-12-31 | $-171.51 Million | $-24.13 Million | 0.141x | +18.57% |
| 2012-12-31 | $-125.61 Million | $-14.90 Million | 0.119x | -- |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehe… Read more